Poolbeg Pharma (LON:POLB) Shares Up 4.3% – Should You Buy?

Poolbeg Pharma PLC (LON:POLB) shares were up 4.3% during trading on Tuesday . The stock traded as high as GBX 7.30 and last traded at GBX 7.20. 4,499,113 shares traded hands during trading, an increase of 143% from the average session volume of 1,853,145 shares. The stock had previously closed at GBX 6.90.

Analyst Upgrades and Downgrades

Separately, Shore Capital Group reaffirmed a “house stock” rating on shares of Poolbeg Pharma in a research report on Monday, July 13th.

Poolbeg Pharma Stock Performance

The firm has a fifty day moving average price of GBX 6.95 and a 200 day moving average price of GBX 5.35. The company has a market cap of £56.27 million, a price-to-earnings ratio of -8.49 and a beta of 1.81.

Poolbeg Pharma Company Profile

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.